Genetic disruption and pharmacological inhibition of PCSK9 have been proven to decrease pulmonary fibrosis, liver fibrosis, and renal fibrosis [20,21,22], but the underlying mechanisms of the pro-fibrogenic effect have not been fully elucidated. The gene discussed is PCSK9; the disease is pulmonary fibrosis.